10 news items
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
RYTM
22 May 24
. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy. In growing children
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
RYTM
6 May 24
setmelanotide. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide
Rhythm Pharmaceuticals Announces Publication Of Results From Phase 2 Study Of Setmelanotide For The Treatment Of Hypothalamic Obesity In The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
the melanocortin-4 receptor (MC4R) pathway and is responsible for controlling physiological functions such as hunger and weight regulation. It most
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
RYTM
29 Apr 24
, which includes the melanocortin-4 receptor (MC4R) pathway and is responsible for controlling physiological functions such as hunger and weight
Analyst Expectations For Rhythm Pharmaceuticals's Future
RYTM
26 Apr 24
their response to recent developments related to Rhythm Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state
q21lh801ms6 d7momgmk71y191lbti3iovbh7metepz
RYTM
24 Apr 24
periodically assess response to setmelanotide therapy. In growing children, the impact of weight loss on growth and maturation should be evaluated
ezfdzutlzd94rxw51gi
RYTM
16 Apr 24
and discontinue setmelanotide. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy
k1wse81tp3fzg3flhk javylnewmx01suk8uyk8u5n1m0wc1agzk4wrwtj8b
RYTM
10 Apr 24
Key Insights:
Action Taken: In response to dynamic market conditions and company
di1n3abqx 6uzyzeqnpzkr56wz0540
RYTM
11 Mar 24
setmelanotide. Pediatric Population: The prescribing physician should periodically assess response to setmelanotide therapy
7vpqmvzrs2da6sc4jl3s hnz
RYTM
6 Mar 24
periodically assess response to setmelanotide therapy. In growing children, the impact of weight loss on growth and maturation should be evaluated. In Europe
- Prev
- 1
- Next